Related Experiment Video

Updated: Feb 18, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.4K

Complications Assoicated with MIRAgel for Treatment of Retinal Detachment

Miin Roh1, Nahyoung Grace Lee1, John B Miller1

  • 1a Department of Ophthalmology , Massachusetts Eye and Ear, Harvard Medical School , Boston MA , USA.

Seminars in Ophthalmology
|November 18, 2017
PubMed

Insights

The MIRAgel hydrogel buckle, used for retinal detachment, can expand over time causing serious complications. Implant removal is difficult and has a high rate of re-detachment.

Area of Science:

  • Ophthalmology
  • Biomaterials Science

Background:

  • The MIRAgel hydrogel buckle was developed in 1979 as a scleral implant for retinal detachment treatment.
  • Long-term studies indicate potential complications associated with its use.

Purpose of the Study:

  • To evaluate the long-term outcomes and complications of the MIRAgel hydrogel buckle in retinal detachment surgery.

Main Methods:

  • Analysis of long-term follow-up data (over 10 years) of patients treated with MIRAgel implants.
  • Review of complication types and outcomes following implant removal.

Main Results:

  • Hydrolysis of the synthetic hydrophilic material causes significant expansion.
  • Complications include buckle extrusion/intrusion, motility disorders, cosmetic deformities, and infections.
  • Implant removal is challenging due to material friability, scleral ectasia, and high redetachment rates.

Conclusions:

  • The MIRAgel hydrogel buckle is associated with significant long-term complications due to material degradation.
  • Surgical removal of complicated implants presents technical difficulties and risks of recurrent retinal detachment.
Keywords:
ComplicationMIRAgelretinal detachmentscleral buckle

More Related Videos

Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats04:16

Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats

Published on: March 7, 2025

1.1K
Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate05:58

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Published on: September 11, 2013

21.5K

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K